| 51 |
30895821 | Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan. | 2019 May |
1 |
| 52 |
30905064 | Chronic heart failure: advances in pharmacological treatment and future perspectives. | 2019 Mar 11 |
1 |
| 53 |
31074791 | Sacubitril/valsartan augments postprandial plasma concentrations of active GLP-1 when combined with sitagliptin in men. | 2019 May 10 |
1 |
| 54 |
31475794 | Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. | 2019 Oct 24 |
1 |
| 55 |
31521679 | Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. | 2019 Nov |
1 |
| 56 |
31764806 | Use of sacubitril/valsartan in Marfan syndrome-related cardiomyopathy: The first case report. | 2019 Nov |
1 |
| 57 |
28527109 | Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. | 2018 Jan |
2 |
| 58 |
29035000 | Use of sacubitril/valsartan in acute decompensated heart failure: a case report. | 2018 Feb |
1 |
| 59 |
29180454 | Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension. | 2018 Jan |
1 |
| 60 |
29374807 | The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. | 2018 Jan 27 |
3 |
| 61 |
29464879 | Insights into implementation of sacubitril/valsartan into clinical practice. | 2018 Jun |
1 |
| 62 |
29500454 | The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients. | 2018 Mar 2 |
1 |
| 63 |
29532764 | Entresto, a New Panacea for Heart Failure? | 2018 |
1 |
| 64 |
29542073 | Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure. | 2018 |
1 |
| 65 |
29643067 | Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). | 2018 Apr |
1 |
| 66 |
29687191 | Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. | 2018 Apr 23 |
1 |
| 67 |
29746915 | Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. | 2018 Aug |
2 |
| 68 |
29754651 | Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). | 2018 May |
2 |
| 69 |
29776559 | Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. | 2018 Aug 1 |
1 |
| 70 |
29957605 | Combined angiotensin receptor and neprilysin inhibition therapy for heart failure. | 2018 Jul |
1 |
| 71 |
30122239 | Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. | 2018 Jul |
2 |
| 72 |
30281045 | [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]. | 2018 Oct |
2 |
| 73 |
30347271 | A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. | 2018 Nov |
1 |
| 74 |
30761275 | Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure-A Comparative Review. | 2018 |
1 |
| 75 |
27324506 | Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. | 2017 Jun |
1 |
| 76 |
27542885 | Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. | 2017 Feb |
2 |
| 77 |
27766748 | Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. | 2017 Feb |
1 |
| 78 |
27868321 | Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. | 2017 Jan |
2 |
| 79 |
28004291 | Sacubitril/Valsartan (LCZ696) in Heart Failure. | 2017 |
2 |
| 80 |
28024961 | Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. | 2017 Sep |
1 |
| 81 |
28030431 | Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. | 2017 Apr |
1 |
| 82 |
28060547 | The safety of sacubitril-valsartan for the treatment of chronic heart failure. | 2017 Feb |
2 |
| 83 |
28176581 | Correction. | 2017 Feb 8 |
2 |
| 84 |
28244205 | What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? | 2017 Jun |
1 |
| 85 |
28281174 | Potential Expanded Indications for Neprilysin Inhibitors. | 2017 Apr |
1 |
| 86 |
28285069 | Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. | 2017 Jun |
1 |
| 87 |
28315356 | The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. | 2017 May 15 |
1 |
| 88 |
28377431 | The renal and cardiovascular effects of natriuretic peptides. | 2017 Jun 1 |
1 |
| 89 |
28378286 | Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF. | 2017 May |
2 |
| 90 |
28417439 | Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. | 2017 Dec |
2 |
| 91 |
28512738 | First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice. | 2017 Aug |
2 |
| 92 |
28587583 | Angiotensin Receptor-Neprilysin Inhibition. | 2017 Jul |
1 |
| 93 |
28652105 | Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. | 2017 Jul |
2 |
| 94 |
28662936 | Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. | 2017 Jul |
1 |
| 95 |
28689178 | Sacubitril/valsartan: beyond natriuretic peptides. | 2017 Oct |
4 |
| 96 |
28720639 | Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results. | 2017 Jul-Aug |
1 |
| 97 |
28844335 | Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. | 2017 Sep |
2 |
| 98 |
29129252 | Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). | 2017 Nov |
1 |
| 99 |
29286056 | Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. | 2017 Oct |
1 |
| 100 |
26280447 | LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. | 2016 Jan |
2 |